Wells Fargo lowered the firm’s price target on Alnylam to $161 from $171 and keeps an Equal Weight rating on the shares. The firm believes the risk/reward remains balanced and awaits a cleaner entry point post-HELIOS-B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALNY:
- Alnylam initiated with a Peer Perform at Wolfe Research
- Alnylam price target lowered to $176 from $184 at Morgan Stanley
- Is ALNY a Buy, Before Earnings?
- Chardan lays out top 4 biotech picks for 2024
- Ionis Pharmaceuticals price target raised to $70 from $65 at RBC Capital
Questions or Comments about the article? Write to editor@tipranks.com